The National Comprehensive Cancer Network (NCCN) has recently published new practical guidelines for pediatric soft tissue sarcoma care, according to a press release from the NCCN.1,2 These guidelines focus specifically on rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in patients under 20 years of age.
Treatment for RMS generally consists of chemotherapy, surgery, and radiation therapy, all of which must be adapted to fit the patient’s risk group, age, and developmental stage. The guidelines were curated with the intent to balance the goal of cure with minimizing the risk of acute adverse effects (AEs).
“Most cancers that occur in children are fundamentally different from cancers occurring in adults,” said Stephen Skapek, MD, chief of the Division of Pediatric Hematology-Oncology at Duke Cancer…